Has Jeffrey Wang, MD received payments from drug or device companies?

Yes. Drug and device makers reported $31,602 in general payments to Jeffrey Wang, MD across 735 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Jeffrey Wang, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Jeffrey Wang, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Jeffrey Wang, MD

Pain Medicine · Honolulu, HINPI 1457418386

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $23,707 of the $31,602 with a category attached, or 75.0%. 45 manufacturers reported payments, led by Medtronic at 50.2% of the total. Reporting peaked in 2019 at $7,370 and has fallen 61.7% since, to $2,824 in 2025.

$31,602in general payments, 2019–2025

Across 735 payments — averaging $43.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Medtronic$16K
Abbott$4K
Boston Scientific$3K
Vertiflex, Inc.$1K
AbbVie$1K
Nevro Corp.$1K
plus $5K from 39 others

What the payments were for

Travel & lodging$7,81625%
Food & beverage$23,70775%
Education$790%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Medtronic(3 entities)	327	$15,869
Abbott	79	$3,906
Boston Scientific	63	$2,792
Vertiflex, Inc.	17	$1,320
AbbVie(2 entities)	40	$1,243
Nevro Corp.	38	$1,004
Spinal Simplicity, LLC	10	$752
Biotronik NRO, Inc.	19	$672
Avanos Medical	5	$478
Arbor Pharmaceuticals, Inc.	25	$354
Si-bone, Inc.	4	$335
Pfizer	12	$245
MML US, Inc.	5	$223
Takeda Pharmaceuticals U.S.A., Inc.	9	$200
Amgen	3	$186
Eisai Inc.	11	$176
Relievant Medsystems, Inc.	1	$136
Vertex	2	$134
Painteq LLC	3	$133
Tersera Therapeutics LLC	5	$132
Globus Medical	1	$114
Radius Health, Inc.	4	$109
Daiichi Sankyo Inc.	9	$105
Biohaven Pharmaceutical Holding Company Ltd.	5	$103
Merz Pharmaceuticals, LLC	3	$84
Biohaven Pharmaceuticals, Inc.	4	$77
Stryker	3	$69
IBSA Pharma Inc.	3	$64
GRT US Holding, Inc.	2	$61
Team_makena_llc	1	$59
Curonix LLC	3	$55
Pacira Pharmaceuticals Incorporated	2	$53
Novartis	2	$43
Hydrocision, Inc.	1	$41
Scilex Pharmaceuticals Inc.	2	$40
Kowa Pharmaceuticals America, Inc.	2	$35
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	2	$31
Merz North America, Inc.	1	$28
Orthofix Medical, Inc.	1	$25
Lilly USA, LLC	1	$24
Teva Pharmaceuticals USA, Inc.	1	$19
Cumberland Pharmaceuticals, Inc.	1	$19
Merck	1	$19
Piramal Critical Care	1	$18
Pacira Therapeutics, Inc.	1	$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few pain medicine providers in Hawaiito place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024

$130,469

Medicare patients

209

Services billed

4,522

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
OxycontinOxycodone Hcl	91	$164,846
MovantikNaloxegol Oxalate	11	$7,230
Morphine Sulfate ErMorphine Sulfate	159	$5,759
Fentanyl	45	$4,527
Venlafaxine Hcl ErVenlafaxine Hcl	32	$4,209
Oxycodone Hcl	203	$3,380
Gabapentin	92	$2,913
Hydromorphone Hcl	42	$2,209
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen	90	$2,132
Tramadol Hcl ErTramadol Hcl	22	$1,587
Methadone Hcl	80	$1,085
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen	55	$1,068
Pregabalin	57	$892
Methylphenidate Hcl	24	$735
Celecoxib	17	$732

Paid to pharmacies, not to this prescriber.

Other pain medicine in Honolulu

Troy TadaHonolulu$18K
Eric SunHonolulu$6K
Louis PauHonolulu$4K
Nicholas MuraokaHonolulu$2K
Daniel BurdickHonolulu$994
Robert HymanHonolulu$564
Roy EsakiHonolulu$91
John SheehanHonolulu$79
Daniel FischbergHonolulu$20
Daniel ChoiKoloa$35K

See the full list for Hawaii →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →